跳到正文
原文
Endpoints News 生物医药· Anna Brown·· 20 小时前AI 评分35

AbbVie 与 Disco 生物制药达成高达 2.54 亿美元合作开发实体瘤靶向药物

AbbVie and Disco strike deal worth up to $2.54B for solid tumor targets

AI 导读

AbbVie 与德国 Disco 生物制药达成合作协议,将共同开发抗体偶联药物和 T 细胞接合器,合作金额最高达 2.54 亿美元。

正文

Ab­b­Vie is part­ner­ing with pre­clin­i­cal can­cer biotech Dis­co Phar­ma­ceu­ti­cals to build out its an­ti­body-drug con­ju­gate and T cell en­gager pro­grams.

The Cologne, Ger­many-based biotech will …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news